- Home
- STAI vs MEIP Comparison
STAI vs MEIP Comparison
Compare STAI & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- MEIP
- Stock Information
- Founded
- STAI 2011
- MEIP 2000
- Country
- STAI United States
- MEIP United States
- Employees
- STAI N/A
- MEIP 28
- Industry
- STAI
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- STAI
- MEIP Health Care
- Exchange
- STAI Nasdaq
- MEIP Nasdaq
- Market Cap
- STAI 16.4M
- MEIP 153.9M
- IPO Year
- STAI N/A
- MEIP 2003
- Fundamental
- Price
- STAI $0.58
- MEIP $4.87
- Analyst Decision
- STAI
- MEIP
- Analyst Count
- STAI 0
- MEIP 0
- Target Price
- STAI N/A
- MEIP N/A
- AVG Volume (30 Days)
- STAI 19.5M
- MEIP 3.0M
- Earning Date
- STAI 01-01-0001
- MEIP 09-18-2025
- Dividend Yield
- STAI N/A
- MEIP N/A
- EPS Growth
- STAI N/A
- MEIP N/A
- EPS
- STAI N/A
- MEIP N/A
- Revenue
- STAI $907,637.00
- MEIP N/A
- Revenue This Year
- STAI N/A
- MEIP N/A
- Revenue Next Year
- STAI N/A
- MEIP N/A
- P/E Ratio
- STAI N/A
- MEIP N/A
- Revenue Growth
- STAI 247.64
- MEIP 33.76
- 52 Week Low
- STAI $0.56
- MEIP $1.46
- 52 Week High
- STAI $9.07
- MEIP $9.00
- Technical
- Relative Strength Index (RSI)
- STAI N/A
- MEIP 54.95
- Support Level
- STAI N/A
- MEIP $4.87
- Resistance Level
- STAI N/A
- MEIP $5.26
- Average True Range (ATR)
- STAI 0.00
- MEIP 1.03
- MACD
- STAI 0.00
- MEIP -0.11
- Stochastic Oscillator
- STAI 0.00
- MEIP 32.30
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.